계명대학교 의학도서관 Repository

Serum FAM19A5 in Neuromyelitis Optica Spectrum Disorders: Can It Be a New Biomarker Representing Clinical Status?

Metadata Downloads
Author(s)
Hye Lim LeeHung Youl SeokHan-Wook RyuEun Bee ChoBong Chul KimByoung Joon KimJu-Hong MinJin Myoung SeokHa Young ShinSa-Yoon KangOh-Hyun KwonSang-Soo LeeJeeyoung OhEun-Hee SohnSo-Young HuhJoong-Yang ChoJae Young SeongByung-Jo Kim
Keimyung Author(s)
Seok, Hung Youl
Department
Dept. of Neurology (신경과학)
Journal Title
Multiple sclerosis
Issued Date
2019
Keyword
Neuromyelitis optica spectrum disorderFAM19A5astrocytereactive gliosisCNS demyelinating diseaseMOG associated disease
Abstract
Background:
Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage.

Objective:
To investigate the significance of serum FAM19A5 in patients with NMOSD.

Methods:
We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls.

Results:
The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack (p < 0.001) and number of past attacks (p = 0.010) were independently associated with increased serum FAM19A5.

Conclusion:
Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4.
Keimyung Author(s)(Kor)
석흥열
Publisher
School of Medicine (의과대학)
Citation
Hye Lim Lee et al. (2019). Serum FAM19A5 in Neuromyelitis Optica Spectrum Disorders: Can It Be a New Biomarker Representing Clinical Status? Multiple sclerosis. doi: 10.1177/1352458519885489
Type
Article
ISSN
1477-0970
Source
https://journals.sagepub.com/doi/full/10.1177/1352458519885489
DOI
10.1177/1352458519885489
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42393
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Neurology (신경과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.